

Maria Zambon

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6653194/maria-zambon-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

196
papers

16,412
citations

55
h-index

126
g-index

208
ext. papers

22,525
ext. citations

11.9
avg, IF

6.54
L-index

#	Paper	IF	Citations
196	Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines.. <i>New England Journal of Medicine</i> , 2022 ,	59.2	65
195	Adverse Events of Interest Following Influenza Vaccination in the First Season of Adjuvanted Trivalent Immunization: Retrospective Cohort Study.. <i>JMIR Public Health and Surveillance</i> , 2022 , 8, e25803 ^{11.4}		
194	Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response among individuals in clinical risk groups.. <i>Journal of Infection</i> , 2022 ,	18.9	20
193	Implementation and Extended Evaluation of the Euroimmun Anti-SARS-CoV-2 IgG Assay and Its Contribution to the United Kingdom's COVID-19 Public Health Response.. <i>Microbiology Spectrum</i> , 2022 , 10, e0228921	8.9	
192	Secondary attack rates in primary and secondary school bubbles following a confirmed case: Active, prospective national surveillance, November to December 2020, England.. <i>PLoS ONE</i> , 2022 , 17, e0262513 ^{3.7}		0
191	Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant.. <i>New England Journal of Medicine</i> , 2022 ,	59.2	224
190	Emergence of the delta variant and risk of SARS-CoV-2 infection in secondary school students and staff: Prospective surveillance in 18 schools, England.. <i>EClinicalMedicine</i> , 2022 , 45, 101319	11.3	0
189	Implementation of corticosteroids in treatment of COVID-19 in the ISARIC WHO Clinical Characterisation Protocol UK: prospective, cohort study.. <i>The Lancet Digital Health</i> , 2022 , 4, e220-e234	14.4	1
188	SARS-CoV-2-specific memory B cells can persist in the elderly who have lost detectable neutralising antibodies. <i>Journal of Clinical Investigation</i> , 2021 ,	15.9	6
187	Reinfection with new variants of SARS-CoV-2 after natural infection: a prospective observational cohort in 13 care homes in England. <i>The Lancet Healthy Longevity</i> , 2021 , 2, e811-e819	9.5	11
186	Epidemiological and clinical characteristics of early COVID-19 cases, United Kingdom of Great Britain and Northern Ireland. <i>Bulletin of the World Health Organization</i> , 2021 , 99, 178-189	8.2	12
185	Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study. <i>Lancet Infectious Diseases</i> , 2021 ,	25.5	150
184	Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK. <i>Lancet Respiratory Medicine</i> , 2021 , 9, 699-711	35.1	54
183	The impact of social and physical distancing measures on COVID-19 activity in England: findings from a multi-tiered surveillance system. <i>Eurosurveillance</i> , 2021 , 26,	19.8	1
182	Infection and transmission of SARS-CoV-2 in London care homes reporting no cases or outbreaks of COVID-19: Prospective observational cohort study, England 2020. <i>Lancet Regional Health - Europe</i> , 2021 , 3, 100038		17
181	SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). <i>Lancet</i> , 2021 , 397, 1459-1469	49.6	268
180	Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study. <i>Lancet Respiratory Medicine</i> , 2021 , 9, 349-359	35.1	70

179	COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. <i>Lancet, The</i> , 2021 , 397, 1725-1735	40	348
178	Interactions between SARS-CoV-2 and influenza, and the impact of coinfection on disease severity: a test-negative design. <i>International Journal of Epidemiology</i> , 2021 , 50, 1124-1133	7.8	50
177	Favipiravir-resistant influenza A virus shows potential for transmission. <i>PLoS Pathogens</i> , 2021 , 17, e1008937	37	6
176	SARS-CoV-2 infection and transmission in primary schools in England in June-December, 2020 (sKIDs): an active, prospective surveillance study. <i>The Lancet Child and Adolescent Health</i> , 2021 , 5, 417-427	14.5	39
175	Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK. <i>Lancet Respiratory Medicine</i> , 2021 , 9, 773-785	35.1	35
174	Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study. <i>Lancet, The</i> , 2021 , 398, 223-237	40	39
173	SARS-CoV-2 infection, antibody positivity and seroconversion rates in staff and students following full reopening of secondary schools in England: A prospective cohort study, September-December 2020. <i>EclinicalMedicine</i> , 2021 , 37, 100948	11.3	6
172	Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels. <i>Transfusion Medicine</i> , 2021 , 31, 167-175	1.3	42
171	Pre-existing influenza-specific nasal IgA or nasal viral infection does not affect live attenuated influenza vaccine immunogenicity in children. <i>Clinical and Experimental Immunology</i> , 2021 , 204, 125-133	6.2	1
170	Inactivated pandemic 2009 H1N1 influenza A virus human vaccines have different efficacy after homologous challenge in the ferret model. <i>Influenza and Other Respiratory Viruses</i> , 2021 , 15, 142-153	5.6	5
169	Influenza and Respiratory Virus Surveillance, Vaccine Uptake, and Effectiveness at a Time of Cocirculating COVID-19: Protocol for the English Primary Care Sentinel System for 2020-2021. <i>JMIR Public Health and Surveillance</i> , 2021 , 7, e24341	11.4	6
168	Mass testing after a single suspected or confirmed case of COVID-19 in London care homes, April-May 2020: implications for policy and practice. <i>Age and Ageing</i> , 2021 , 50, 649-656	3	6
167	Rapid community point-of-care testing for COVID-19 (RAPTOR-C19): protocol for a platform diagnostic study. <i>Diagnostic and Prognostic Research</i> , 2021 , 5, 4	5.5	2
166	Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study. <i>Lancet Rheumatology, The</i> , 2021 , 3, e498-e506	14.2	30
165	Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. <i>New England Journal of Medicine</i> , 2021 , 385, 585-594	59.2	1058
164	Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study. <i>Lancet Microbe, The</i> , 2021 , 2, e354-e365	22.2	61
163	Comparability of six different immunoassays measuring SARS-CoV-2 antibodies with neutralizing antibody levels in convalescent plasma: From utility to prediction. <i>Transfusion</i> , 2021 , 61, 2837-2843	2.9	11
162	Emergence of SARS-CoV-2 Alpha (B.1.1.7) variant, infection rates, antibody seroconversion and seroprevalence rates in secondary school students and staff: Active prospective surveillance, December 2020 to March 2021, England. <i>Journal of Infection</i> , 2021 , 83, 573-580	18.9	5

161	A prenylated dsRNA sensor protects against severe COVID-19. <i>Science</i> , 2021 , 374, eabj3624	33.3	26
160	Changing composition of SARS-CoV-2 lineages and rise of Delta variant in England. <i>EclinicalMedicine</i> , 2021 , 39, 101064	11.3	54
159	Serological profile of first SARS-CoV-2 reinfection cases detected within the SIREN study. <i>Journal of Infection</i> , 2021 ,	18.9	0
158	Antibody persistence and neutralising activity in primary school students and staff: Prospective active surveillance, June to December 2020, England. <i>EclinicalMedicine</i> , 2021 , 41, 101150	11.3	1
157	Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study. <i>Lancet Infectious Diseases</i> , 2020 , 20, 1034-1042	25.5	309
156	Human respiratory syncytial virus and influenza seasonality patterns-Early findings from the WHO global respiratory syncytial virus surveillance. <i>Influenza and Other Respiratory Viruses</i> , 2020 , 14, 638-646	5.6	16
155	Snapshot PCR surveillance for SARS-CoV-2 in hospital staff in England. <i>Journal of Infection</i> , 2020 , 81, 427-434	18.9	21
154	Invasive Mycobacterium chimaera Infections and Heater-Cooler Devices in Cardiac Surgery. <i>Emerging Infectious Diseases</i> , 2020 , 26, 632	10.2	2
153	Use of traditional serological methods and oral fluids to assess immunogenicity in children aged 2-16 years after successive annual vaccinations with LAIV. <i>Vaccine</i> , 2020 , 38, 2660-2670	4.1	3
152	Toward unified molecular surveillance of RSV: A proposal for genotype definition. <i>Influenza and Other Respiratory Viruses</i> , 2020 , 14, 274-285	5.6	15
151	Hand Hygiene Practices and the Risk of Human Coronavirus Infections in a UK Community Cohort. <i>Wellcome Open Research</i> , 2020 , 5, 98	4.8	10
150	Seasonality and immunity to laboratory-confirmed seasonal coronaviruses (HCoV-NL63, HCoV-OC43, and HCoV-229E): results from the Flu Watch cohort study. <i>Wellcome Open Research</i> , 2020 , 5, 52	4.8	29
149	Seasonality and immunity to laboratory-confirmed seasonal coronaviruses (HCoV-NL63, HCoV-OC43, and HCoV-229E): results from the Flu Watch cohort study. <i>Wellcome Open Research</i> , 2020 , 5, 52	4.8	30
148	SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus. <i>Wellcome Open Research</i> , 2020 , 5, 181	4.8	38
147	SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus. <i>Wellcome Open Research</i> , 2020 , 5, 181	4.8	60
146	Household transmission of seasonal coronavirus infections: Results from the Flu Watch cohort study. <i>Wellcome Open Research</i> , 2020 , 5, 145	4.8	3
145	Emergence of a Novel Coronavirus (COVID-19): Protocol for Extending Surveillance Used by the Royal College of General Practitioners Research and Surveillance Centre and Public Health England. <i>JMIR Public Health and Surveillance</i> , 2020 , 6, e18606	11.4	44
144	The Oxford Royal College of General Practitioners Clinical Informatics Digital Hub: Protocol to Develop Extended COVID-19 Surveillance and Trial Platforms. <i>JMIR Public Health and Surveillance</i> , 2020 , 6, e19773	11.4	15

143	Clinical characteristics, predictors, and performance of case definition-Interim results from the WHO global respiratory syncytial virus surveillance pilot. <i>Influenza and Other Respiratory Viruses</i> , 2020 , 14, 647-657	5.6	19
142	Differences in nasal immunoglobulin A responses to influenza vaccine strains after live attenuated influenza vaccine (LAIV) immunization in children. <i>Clinical and Experimental Immunology</i> , 2020 , 199, 109-118	6.2	2
141	Postexposure Prophylaxis With rVSV-ZEBOV Following Exposure to a Patient With Ebola Virus Disease Relapse in the United Kingdom: An Operational, Safety, and Immunogenicity Report. <i>Clinical Infectious Diseases</i> , 2020 , 71, 2872-2879	11.6	6
140	Investigation of SARS-CoV-2 outbreaks in six care homes in London, April 2020. <i>EClinicalMedicine</i> , 2020 , 26, 100533	11.3	54
139	High prevalence of SARS-CoV-2 antibodies in care homes affected by COVID-19: Prospective cohort study, England. <i>EClinicalMedicine</i> , 2020 , 28, 100597	11.3	46
138	Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. <i>Eurosurveillance</i> , 2020 , 25,	19.8	4027
137	Results from the WHO external quality assessment for the respiratory syncytial virus pilot, 2016-17. <i>Influenza and Other Respiratory Viruses</i> , 2020 , 14, 671-677	5.6	6
136	Increased risk of SARS-CoV-2 infection in staff working across different care homes: enhanced CoVID-19 outbreak investigations in London care Homes. <i>Journal of Infection</i> , 2020 , 81, 621-624	18.9	41
135	Excess mortality in the first COVID pandemic peak: cross-sectional analyses of the impact of age, sex, ethnicity, household size, and long-term conditions in people of known SARS-CoV-2 status in England. <i>British Journal of General Practice</i> , 2020 , 70, e890-e898	1.6	19
134	Disparities in the excess risk of mortality in the first wave of COVID-19: Cross sectional study of the English sentinel network. <i>Journal of Infection</i> , 2020 , 81, 785-792	18.9	23
133	COVID-19 in children: analysis of the first pandemic peak in England. <i>Archives of Disease in Childhood</i> , 2020 , 105, 1180-1185	2.2	75
132	Probable Vertical Transmission of SARS-CoV-2 Infection. <i>Pediatric Infectious Disease Journal</i> , 2020 , 39, e257-e260	3.4	22
131	Hand Hygiene Practices and the Risk of Human Coronavirus Infections in a UK Community Cohort. <i>Wellcome Open Research</i> , 2020 , 5, 98	4.8	4
130	Viral Shedding in Recipients of Live Attenuated Influenza Vaccine in the 2016-2017 and 2017-2018 Influenza Seasons in the United Kingdom. <i>Clinical Infectious Diseases</i> , 2020 , 70, 2505-2513	11.6	9
129	Leveraging the Global Influenza Surveillance and Response System for global respiratory syncytial virus surveillance-opportunities and challenges. <i>Influenza and Other Respiratory Viruses</i> , 2020 , 14, 622-629	5.6	7
128	Nosocomial transmission of influenza: A retrospective cross-sectional study using next generation sequencing at a hospital in England (2012-2014). <i>Influenza and Other Respiratory Viruses</i> , 2019 , 13, 556-563	5.6	10
127	The epidemiological signature of influenza B virus and its B/Victoria and B/Yamagata lineages in the 21st century. <i>PLoS ONE</i> , 2019 , 14, e0222381	3.7	42
126	Prophylactic efficacy of a human monoclonal antibody against MERS-CoV in the common marmoset. <i>Antiviral Research</i> , 2019 , 163, 70-74	10.8	8

125	End of season influenza vaccine effectiveness in adults and children in the United Kingdom in 2017/18. <i>Eurosurveillance</i> , 2019 , 24,	19.8	19
124	Serological surveillance of influenza in an English sentinel network: pilot study protocol. <i>BMJ Open</i> , 2019 , 9, e024285	3	11
123	Determining the Mutation Bias of Favipiravir in Influenza Virus Using Next-Generation Sequencing. <i>Journal of Virology</i> , 2019 , 93,	6.6	31
122	Effects of seasonal and pandemic influenza on health-related quality of life, work and school absence in England: Results from the Flu Watch cohort study. <i>Influenza and Other Respiratory Viruses</i> , 2018 , 12, 171-182	5.6	25
121	Estimating the burden on general practitioner services in England from increases in respiratory disease associated with seasonal respiratory pathogen activity. <i>Epidemiology and Infection</i> , 2018 , 146, 1389-1396	4.3	10
120	Urgent challenges in implementing live attenuated influenza vaccine. <i>Lancet Infectious Diseases, The</i> , 2018 , 18, e25-e32	25.5	29
119	The mechanism of resistance to favipiravir in influenza. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, 11613-11618	11.5	160
118	Mycobacterium chimaera infection following cardiac surgery in the United Kingdom: clinical features and outcome of the first 30 cases. <i>Clinical Microbiology and Infection</i> , 2018 , 24, 1164-1170	9.5	44
117	The burden of seasonal respiratory infections on a national telehealth service in England. <i>Epidemiology and Infection</i> , 2017 , 145, 1922-1932	4.3	8
116	The emergence of enterovirus D68 in England in autumn 2014 and the necessity for reinforcing enterovirus respiratory screening. <i>Epidemiology and Infection</i> , 2017 , 145, 1855-1864	4.3	6
115	Insidious Risk of Severe Mycobacterium chimaera Infection in Cardiac Surgery Patients. <i>Clinical Infectious Diseases</i> , 2017 , 64, 335-342	11.6	103
114	Cohort Profile: The Flu Watch Study. <i>International Journal of Epidemiology</i> , 2017 , 46, e18	7.8	19
113	Antibody-based assay discriminates Zika virus infection from other flaviviruses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017 , 114, 8384-8389	11.5	129
112	Global outbreak of severe Mycobacterium chimaera disease after cardiac surgery: a molecular epidemiological study. <i>Lancet Infectious Diseases, The</i> , 2017 , 17, 1033-1041	25.5	136
111	Can defective interfering RNAs affect the live attenuated influenza vaccine? - Authors'Reply. <i>Lancet Infectious Diseases, The</i> , 2017 , 17, 1235-1236	25.5	2
110	Comparison of mucosal lining fluid sampling methods and influenza-specific IgA detection assays for use in human studies of influenza immunity. <i>Journal of Immunological Methods</i> , 2017 , 449, 1-6	2.5	9
109	The potential risks and impact of the start of the 2015-2016 influenza season in the WHO European Region: a rapid risk assessment. <i>Influenza and Other Respiratory Viruses</i> , 2016 , 10, 236-246	5.6	11
108	Adjuvanted influenza-H1N1 vaccination reveals lymphoid signatures of age-dependent early responses and of clinical adverse events. <i>Nature Immunology</i> , 2016 , 17, 204-13	19.1	101

107	Temporal Patterns of Influenza A and B in Tropical and Temperate Countries: What Are the Lessons for Influenza Vaccination?. <i>PLoS ONE</i> , 2016 , 11, e0152310	3.7	44
106	Rapid generation of a human monoclonal antibody to combat Middle East respiratory syndrome. <i>Journal of Infection and Public Health</i> , 2016 , 9, 231-5	7.4	33
105	Late Ebola virus relapse causing meningoencephalitis: a case report. <i>Lancet, The</i> , 2016 , 388, 498-503	4.0	236
104	Natural T Cell-mediated Protection against Seasonal and Pandemic Influenza. Results of the Flu Watch Cohort Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015 , 191, 1422-31	10.2	156
103	Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, 10473-8	11.5	170
102	Harmonizing influenza primary-care surveillance in the United Kingdom: piloting two methods to assess the timing and intensity of the seasonal epidemic across several general practice-based surveillance schemes. <i>Epidemiology and Infection</i> , 2015 , 143, 1-12	4.3	34
101	Effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2014/15 end of season results. <i>Eurosurveillance</i> , 2015 , 20,	19.8	69
100	Self-sampling for community respiratory illness: a new tool for national virological surveillance. <i>Eurosurveillance</i> , 2015 , 20, 21058	19.8	15
99	Accumulation of human-adapting mutations during circulation of A(H1N1)pdm09 influenza virus in humans in the United Kingdom. <i>Journal of Virology</i> , 2014 , 88, 13269-83	6.6	58
98	London 2012 Olympic and Paralympic Games: public health surveillance and epidemiology. <i>Lancet, The</i> , 2014 , 383, 2083-2089	4.0	55
97	Enhanced MERS coronavirus surveillance of travelers from the Middle East to England. <i>Emerging Infectious Diseases</i> , 2014 , 20, 1562-4	10.2	25
96	A mouse model for Betacoronavirus subgroup 2c using a bat coronavirus strain HKU5 variant. <i>MBio</i> , 2014 , 5, e00047-14	7.8	47
95	An H7N1 influenza virus vaccine induces broadly reactive antibody responses against H7N9 in humans. <i>Vaccine Journal</i> , 2014 , 21, 1153-63		47
94	Developments in the treatment of severe influenza: lessons from the pandemic of 2009 and new prospects for therapy. <i>Current Opinion in Infectious Diseases</i> , 2014 , 27, 560-5	5.4	13
93	Administration of AS03B-adjuvanted A(H1N1)pdm09 vaccine in children aged . <i>Clinical Infectious Diseases</i> , 2014 , 58, 181-7	11.6	8
92	Comparative community burden and severity of seasonal and pandemic influenza: results of the Flu Watch cohort study. <i>Lancet Respiratory Medicine, the</i> , 2014 , 2, 445-54	35.1	266
91	Open source clinical science for emerging infections. <i>Lancet Infectious Diseases, The</i> , 2014 , 14, 8-9	25.5	58
90	Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses. <i>Molecular Therapy</i> , 2014 , 22, 233-8	11.7	80

89	Effectiveness of seasonal influenza vaccination during pregnancy in preventing influenza infection in infants, England, 2013/14. <i>Eurosurveillance</i> , 2014 , 19, 20959	19.8	58
88	Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. <i>Journal of Virology</i> , 2013 , 87, 7790-2	6.6	796
87	Virological self-sampling to monitor influenza antiviral susceptibility in a community cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 2324-31	5.1	5
86	Age-specific vaccine effectiveness of seasonal 2010/2011 and pandemic influenza A(H1N1) 2009 vaccines in preventing influenza in the United Kingdom. <i>Epidemiology and Infection</i> , 2013 , 141, 620-30	4.3	40
85	Multi-centre observational study of transplacental transmission of influenza antibodies following vaccination with AS03(A)-adjuvanted H1N1 2009 vaccine. <i>PLoS ONE</i> , 2013 , 8, e47448	3.7	9
84	Mortality attributable to influenza in England and Wales prior to, during and after the 2009 pandemic. <i>PLoS ONE</i> , 2013 , 8, e79360	3.7	27
83	Efficient boosting of the antiviral T cell response in B cell-depleted patients with autoimmune rheumatic diseases following influenza vaccination. <i>Clinical and Experimental Rheumatology</i> , 2013 , 31, 723-30	2.2	9
82	Improving influenza vaccine virus selection: report of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14-16 June 2010. <i>Influenza and Other Respiratory Viruses</i> , 2012 , 6, 142-52, e1-5	5.6	55
81	Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives. <i>Lancet Infectious Diseases, The</i> , 2012 , 12, 240-8	25.5	159
80	Seroprevalence of influenza A(H1N1)pdm09 virus antibody, England, 2010 and 2011. <i>Emerging Infectious Diseases</i> , 2012 , 18, 1894-7	10.2	23
79	Evolutionary dynamics of local pandemic H1N1/2009 influenza virus lineages revealed by whole-genome analysis. <i>Journal of Virology</i> , 2012 , 86, 11-8	6.6	87
78	Microbiological aspects of public health planning and preparedness for the 2012 Olympic Games. <i>Epidemiology and Infection</i> , 2012 , 140, 2142-51	4.3	11
77	Fatal cases of influenza A(H3N2) in children: insights from whole genome sequence analysis. <i>PLoS ONE</i> , 2012 , 7, e33166	3.7	16
76	Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012. <i>Eurosurveillance</i> , 2012 , 17, 20290	19.8	264
75	Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial. <i>Lancet Infectious Diseases, The</i> , 2011 , 11, 91-101	25.5	80
74	Adjuvanted or whole-virion vaccine for 2009 influenza A (H1N1) [AuthorsReply]. <i>Lancet Infectious Diseases, The</i> , 2011 , 11, 497-498	25.5	1
73	Oseltamivir-resistant pandemic (H1N1) 2009 virus infection in England and Scotland, 2009-2010. <i>Emerging Infectious Diseases</i> , 2011 , 17, 1807-15	10.2	20
72	Evolutionary pathways of the pandemic influenza A (H1N1) 2009 in the UK. <i>PLoS ONE</i> , 2011 , 6, e23779	3.7	33

71	Evaluation of the antiviral drug susceptibility of influenza viruses in Italy from 2004/05 to 2009/10 epidemics and from the recent 2009 pandemic. <i>Antiviral Research</i> , 2011 , 90, 205-12	10.8	13
70	Use of antiviral drugs to reduce household transmission of pandemic (H1N1) 2009, United Kingdom. <i>Emerging Infectious Diseases</i> , 2011 , 17, 990-9	10.2	37
69	Nucleic acid dipstick test for molecular diagnosis of pandemic H1N1. <i>Journal of Clinical Microbiology</i> , 2010 , 48, 3608-13	9.7	16
68	Estimating influenza vaccine effectiveness using routinely collected laboratory data. <i>Journal of Epidemiology and Community Health</i> , 2010 , 64, 1062-7	5.1	54
67	Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. <i>Lancet, The</i> , 2010 , 375, 1100-8	4.0	578
66	Pandemic (H1N1) 2009 influenza in the UK: clinical and epidemiological findings from the first few hundred (FF100) cases. <i>Epidemiology and Infection</i> , 2010 , 138, 1531-41	4.3	57
65	Antiviral drug profile of seasonal influenza viruses circulating in Portugal from 2004/2005 to 2008/2009 winter seasons. <i>Antiviral Research</i> , 2010 , 86, 128-36	10.8	12
64	A randomised, partially observer blind, multicentre, head-to-head comparison of a two-dose regimen of Baxter and GlaxoSmithKline H1N1 pandemic vaccines, administered 21 days apart. <i>Health Technology Assessment</i> , 2010 , 14, 193-334	4.4	8
63	Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 7962-7	11.5	204
62	Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children. <i>Clinical Infectious Diseases</i> , 2009 , 48, 389-96	11.6	148
61	Monitoring the emergence of community transmission of influenza A/H1N1 2009 in England: a cross sectional opportunistic survey of self sampled telephone callers to NHS Direct. <i>BMJ, The</i> , 2009 , 339, b3403	5.9	39
60	Personal protective equipment and risk for avian influenza (H7N3). <i>Emerging Infectious Diseases</i> , 2009 , 15, 59-62	10.2	19
59	The immunogenicity of a cell-derived H7N1 split influenza virion vaccine in mice. <i>Scandinavian Journal of Immunology</i> , 2009 , 69, 576-8	3.4	1
58	A cell-based H7N1 split influenza virion vaccine confers protection in mouse and ferret challenge models. <i>Influenza and Other Respiratory Viruses</i> , 2009 , 3, 107-17	5.6	32
57	Surveillance for neuraminidase-inhibitor-resistant influenza viruses in Japan, 1996-2007. <i>Antiviral Therapy</i> , 2009 , 14, 751-61	1.6	62
56	Oseltamivir-Resistant Influenza Virus A (H1N1), Europe, 2007-08 Season. <i>Emerging Infectious Diseases</i> , 2009 , 15, 552-560	10.2	292
55	Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (rsv) vaccines--nonadjuvanted vaccine or vaccine adjuvanted with alum--given concomitantly with influenza vaccine to high-risk elderly individuals. <i>Journal of Infectious Diseases</i> , 2008 , 198, 1317-26	7	77
54	The evolution of norovirus, the "gastric flu". <i>PLoS Medicine</i> , 2008 , 5, e42	11.6	45

53	Linking syndromic surveillance with virological self-sampling. <i>Epidemiology and Infection</i> , 2008 , 136, 222-43	4.3	30
52	Respiratory syncytial virus infection in infants admitted to paediatric intensive care units in London, and in their families. <i>European Journal of Pediatrics</i> , 2008 , 167, 395-9	4.1	23
51	Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans. <i>Journal of Clinical Investigation</i> , 2008 , 118, 4036-48	15.9	258
50	Alterations in receptor binding properties of recent human influenza H3N2 viruses are associated with reduced natural killer cell lysis of infected cells. <i>Journal of Virology</i> , 2007 , 81, 11170-8	6.6	48
49	A sensitive retroviral pseudotype assay for influenza H5N1-neutralizing antibodies. <i>Influenza and Other Respiratory Viruses</i> , 2007 , 1, 105-12	5.6	105
48	SARS transmission in Vietnam outside of the health-care setting. <i>Epidemiology and Infection</i> , 2007 , 135, 392-401	4.3	19
47	Perspectives in interpandemic influenza. <i>IDrugs: the Investigational Drugs Journal</i> , 2007 , 10, 861-4		
46	Reply to Skowronski et al.. <i>Journal of Infectious Diseases</i> , 2006 , 193, 900-901	7	2
45	Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. <i>Antimicrobial Agents and Chemotherapy</i> , 2006 , 50, 2395-402	5.9	295
44	First external quality assurance of antibody diagnostic for SARS-new coronavirus. <i>Journal of Clinical Virology</i> , 2005 , 34, 22-5	14.5	20
43	Subcellular localization of the severe acute respiratory syndrome coronavirus nucleocapsid protein. <i>Journal of General Virology</i> , 2005 , 86, 3303-3310	4.9	65
42	Neuraminidase Inhibitor Susceptibility Network Position Statement: Antiviral Resistance in Influenza A/H5N1 Viruses. <i>Antiviral Therapy</i> , 2005 , 10, 873-877	1.6	37
41	Influenza among U.K. pilgrims to hajj, 2003. <i>Emerging Infectious Diseases</i> , 2004 , 10, 1882-3	10.2	46
40	Restrictions to the adaptation of influenza a virus h5 hemagglutinin to the human host. <i>Journal of Virology</i> , 2004 , 78, 502-7	6.6	54
39	Epidemiological features of a new strain of the influenza A virus--influenza A (H1N2) circulating in England and its public health implications. <i>Virus Research</i> , 2004 , 103, 53-4	6.4	2
38	The inexact science of influenza prediction. <i>Lancet, The</i> , 2004 , 363, 582-3	4.0	15
37	Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network. <i>Journal of Clinical Microbiology</i> , 2003 , 41, 742-50	9.7	182
36	Severe and unrecognised: pertussis in UK infants. <i>Archives of Disease in Childhood</i> , 2003 , 88, 802-6	2.2	183

35	Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. <i>Antimicrobial Agents and Chemotherapy</i> , 2003 , 47, 2264-72	5.9	240
34	Human metapneumovirus as a cause of community-acquired respiratory illness. <i>Emerging Infectious Diseases</i> , 2002 , 8, 897-901	10.2	229
33	Current research on respiratory viral infections: Fourth International Symposium. <i>Antiviral Research</i> , 2002 , 55, 227-78	10.8	26
32	Experience with the clinical development of influenza vaccines for potential pandemics. <i>Medical Microbiology and Immunology</i> , 2002 , 191, 197-201	4	8
31	Development of vaccines against common colds. <i>British Medical Bulletin</i> , 2002 , 62, 99-111	5.4	15
30	Antibody responses to vaccinations given within the first two years after transplant are similar between autologous peripheral blood stem cell and bone marrow transplant recipients. <i>Bone Marrow Transplantation</i> , 2001 , 28, 775-81	4.4	69
29	Position statement: global neuraminidase inhibitor susceptibility network. <i>Antiviral Research</i> , 2001 , 49, 147-56	10.8	128
28	Diagnosis of influenza in the community: relationship of clinical diagnosis to confirmed virological, serologic, or molecular detection of influenza. <i>Archives of Internal Medicine</i> , 2001 , 161, 2116-22		123
27	Influenza A antigen exposure selects dominant Vbeta17+ TCR in human CD8+ cytotoxic T cell responses. <i>International Immunology</i> , 2001 , 13, 1373-81	4.9	41
26	Response to influenza immunisation during treatment for cancer. <i>Archives of Disease in Childhood</i> , 2001 , 84, 496-500	2.2	57
25	Developing vaccines against potential pandemic influenza viruses. <i>International Congress Series</i> , 2001 , 1219, 751-759		2
24	A single radial haemolysis assay for antibody to H5 haemagglutinin. <i>International Congress Series</i> , 2001 , 1219, 761-766		9
23	Update on influenza and other viral pneumonias. <i>Current Opinion in Infectious Diseases</i> , 2001 , 14, 199-204	5.4	6
22	Population estimates of persons presenting to general practitioners with influenza-like illness, 1987-96: a study of the demography of influenza-like illness in sentinel practice networks in England and Wales, and in The Netherlands. <i>Epidemiology and Infection</i> , 2000 , 124, 245-53	4.3	42
21	Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma. <i>British Journal of Cancer</i> , 2000 , 82, 1261-5	8.7	155
20	Influenza surveillance in England and Wales: October 1999 to May 2000. <i>Communicable Disease and Public Health / Phls</i> , 2000 , 3, 261-6		8
19	Seroconversion after influenza vaccination in patients with lung cancer. <i>British Journal of Cancer</i> , 1999 , 80, 219-20	8.7	72
18	The duration and magnitude of influenza epidemics: a study of surveillance data from sentinel general practices in England, Wales and the Netherlands. <i>European Journal of Epidemiology</i> , 1999 , 15, 467-73	12.1	76

17	Active and passive immunisation against respiratory syncytial virus. <i>Reviews in Medical Virology</i> , 1999 , 9, 227-36	11.7	8
16	Influenza activity in England and Wales: October 1998 to June 1999. <i>Communicable Disease and Public Health / Phls</i> , 1999 , 2, 273-9		5
15	Molecular epidemiology of two consecutive outbreaks of parainfluenza 3 in a bone marrow transplant unit. <i>Journal of Clinical Microbiology</i> , 1998 , 36, 2289-93	9.7	75
14	Sentinel surveillance of influenza in Europe 1997-1998. <i>Eurosurveillance</i> , 1998 , 3, 29-31	19.8	10
13	Laboratory containment for influenza A H5N1 virus: level 2, level 3, or level 3+?. <i>Communicable Disease and Public Health / Phls</i> , 1998 , 1, 71-2		5
12	Influenza surveillance in England and Wales: October 1997 to June 1998. <i>Communicable Disease and Public Health / Phls</i> , 1998 , 1, 244-51		7
11	Response to influenza virus vaccination in vertical HIV infection. <i>Archives of Disease in Childhood</i> , 1997 , 76, 215-8	2.2	19
10	Influenza surveillance in England and Wales: October 1996 to June 1997. <i>Communicable Disease Report CDR Review</i> , 1997 , 7, R212-9		3
9	Influenza surveillance in England and Wales: October 1995 to June 1996. <i>Communicable Disease Report CDR Review</i> , 1996 , 6, R163-9		4
8	Influenza surveillance in England and Wales: October 1994 to June 1995. <i>Communicable Disease Report CDR Review</i> , 1995 , 5, R200-4		2
7	Parvovirus B19 outbreak on an adult ward. <i>Epidemiology and Infection</i> , 1994 , 113, 345-53	4.3	41
6	Antibody capture haemadherence tests for parvovirus B19-specific IgM and IgG. <i>Journal of Virological Methods</i> , 1993 , 45, 27-37	2.6	10
5	The Oxford Royal College of General Practitioners Clinical Informatics Digital Hub: Protocol to Develop Extended COVID-19 Surveillance and Trial Platforms (Preprint)		4
4	Influenza and Respiratory Virus Surveillance, Vaccine Uptake, and Effectiveness at a Time of Cocirculating COVID-19: Protocol for the English Primary Care Sentinel System for 2020-2021 (Preprint)		1
3	COVID-19 in Great Britain: epidemiological and clinical characteristics of the first few hundred (FF100) cases: a descriptive case series and case control analysis		9
2	Transmission dynamics of COVID-19 in household and community settings in the United Kingdom		22
1	Do antibody positive healthcare workers have lower SARS-CoV-2 infection rates than antibody negative healthcare workers? Large multi-centre prospective cohort study (the SIREN study), England: June to November 2020		62